(Q34385273)

English

Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects (English)

1 reference

Europe PubMed Central

1 August 2017

author name string

Kevin J Martin

1

1 reference

Europe PubMed Central

1 August 2017

Gregory Bell

2

1 reference

Europe PubMed Central

1 August 2017

Karen Pickthorn

3

1 reference

Europe PubMed Central

1 August 2017

Saling Huang

4

1 reference

Europe PubMed Central

1 August 2017

Andrew Vick

5

1 reference

Europe PubMed Central

1 August 2017

Peter Hodsman

6

1 reference

Europe PubMed Central

1 August 2017

Munro Peacock

7

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

13 November 2013

1 reference

Europe PubMed Central

1 August 2017

Nephrology Dialysis Transplantation

1 reference

Europe PubMed Central

1 August 2017

29

1 reference

Europe PubMed Central

1 August 2017

2

1 reference

Europe PubMed Central

1 August 2017

385-392

1 reference

Europe PubMed Central

1 August 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

6 October 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

FGF23 induces left ventricular hypertrophy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Area under the curve and other summary indicators of repeated waking cortisol measurements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Calcium-sensing receptor in the brain.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

The extracellular calcium-sensing receptor: its role in health and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

Identification of calcium sensing receptor (CaSR) mRNA-expressing cells in normal and injured rat brain

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

27 October 2018

Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

27 October 2018

Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24235081

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24235081

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/NDT/GFT417

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34385273&oldid=1971774320"